Psoriatic Arthritis Phenotype Clusters and Their Association with Treatment Response: a Real-world Longitudinal Cohort Study from the Psoriatic Arthritis Research Consortium

Overview

Journal Ann Rheum Dis

Date 2025 Feb 7

PMID 39919898

Authors

Paras Karmacharya

Leslie J Crofford

Daniel W Byrne

Alisa Stephens-Shields

M Elaine Husni

Jose U Scher

Ethan Craig

Robert Fitzsimmons

Soumya M Reddy

Marina N Magrey

Jessica A Walsh

Alexis Ogdie

Affiliations

Soon will be listed here.

Abstract

Objectives: To identify phenotype clusters and their trajectories in psoriatic arthritis (PsA) and examine the association of the clusters with treatment response in a real-world setting.

Methods: In the multicentre PsA Research Consortium (PARC) study, we applied factor analysis of mixed data to reduce dimensionality and collinearity, followed by hierarchical clustering on principal components. We then evaluated the transition of PsA clusters and their response to new immunomodulatory therapy and tumour necrosis factor inhibitor (TNFi).

Results: Among 627 patients with PsA, three clusters were identified: mild PsA and psoriasis only (PsO) (Cluster 1, 47.4%), severe PsA and mild PsO (Cluster 2, 34.3%) and severe PsA and severe PsO (Cluster 3, 18.3%). Among 339 patients starting or changing, significant differences in response were observed (mean follow-up of 0.7 years, SD 0.8), with Cluster 3 showing the largest improvements in cDAPSA and PsAID. No differences were found among those starting TNFi (n=218). cDAPSA remission and PsAID patient acceptable symptom state were achieved in 10% and 54%, respectively. Clusters remained stable over time despite treatment changes, though some transitions occurred, notably from Cluster 3 to milder clusters.

Conclusion: Data-driven clusters with distinct therapy responses identified in this real-world study highlight the extensive heterogeneity in PsA and the central role of psoriasis and musculoskeletal severity in treatment outcomes. Concurrently, these findings underscore the need for better outcome measures, particularly for individuals with lower disease activity.

References

Karmacharya P, Crowson C, Lennon R, Poudel D, Davis 3rd J, Ogdie A . Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort. Semin Arthritis Rheum. 2023; 64:152282. PMC: 10872589. DOI: 10.1016/j.semarthrit.2023.152282. View

Lubrano E, Perrotta F, Scriffignano S, Coates L, Helliwell P . Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. Rheumatol Ther. 2019; 6(4):521-528. PMC: 6858418. DOI: 10.1007/s40744-019-00171-w. View

Scrivo R, Giardino A, Salvarani C, Foti R, Afeltra A, Viapiana O . An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. Clin Exp Rheumatol. 2019; 38(1):107-114. View

Tucker L, Coates L, Helliwell P . Assessing Disease Activity in Psoriatic Arthritis: A Literature Review. Rheumatol Ther. 2018; 6(1):23-32. PMC: 6393266. DOI: 10.1007/s40744-018-0132-4. View

Koo T, Nagy Z, Sesztak M, Ujfalussy I, Meretey K, Bohm U . Subsets in psoriatic arthritis formed by cluster analysis. Clin Rheumatol. 2001; 20(1):36-43. DOI: 10.1007/s100670170101. View

Baraliakos X, Pournara E, Coates L, Mease P, Jahandideh S, Gladman D . Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations. Clin Exp Rheumatol. 2023; 42(3):696-701. DOI: 10.55563/clinexprheumatol/b8co74. View

Ritchlin C, Colbert R, Gladman D . Psoriatic Arthritis. N Engl J Med. 2017; 376(10):957-970. DOI: 10.1056/NEJMra1505557. View

Coates L, Kavanaugh A, Mease P, Soriano E, Acosta-Felquer M, Armstrong A . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68(5):1060-71. DOI: 10.1002/art.39573. View

Karmacharya P, Stull C, Stephens-Shields A, Husni M, Scher J, Craig E . Responsiveness and Minimum Clinically Important Difference in Patient-Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care Res (Hoboken). 2023; 75(10):2182-2189. PMC: 11229093. DOI: 10.1002/acr.25111. View

10.

Orbai A, de Wit M, Mease P, Shea J, Gossec L, Leung Y . International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2016; 76(4):673-680. PMC: 5344772. DOI: 10.1136/annrheumdis-2016-210242. View

11.

Orbai A, Holland R, Leung Y, Tillett W, Goel N, Christensen R . PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. J Rheumatol. 2018; 46(8):990-995. PMC: 6571063. DOI: 10.3899/jrheum.181077. View

12.

Ogdie A, Coates L . The Changing Face of Clinical Trials in Psoriatic Arthritis. Curr Rheumatol Rep. 2017; 19(4):21. PMC: 5502109. DOI: 10.1007/s11926-017-0642-z. View

13.

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou C . The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2010; 70(1):25-31. DOI: 10.1136/ard.2010.133645. View

14.

van Gestel A, Prevoo M, van t Hof M, van Rijswijk M, van de Putte L, van Riel P . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against.... Arthritis Rheum. 1996; 39(1):34-40. DOI: 10.1002/art.1780390105. View

15.

Richette P, Vis M, Ohrndorf S, Tillett W, Ramirez J, Neuhold M . Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA. RMD Open. 2023; 9(1). PMC: 10069583. DOI: 10.1136/rmdopen-2022-002934. View

16.

Karmacharya P, Ogdie A, Eder L . Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. Ther Adv Musculoskelet Dis. 2021; 13:1759720X21998279. PMC: 7934027. DOI: 10.1177/1759720X21998279. View

17.

Haroon M, Gallagher P, FitzGerald O . Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2014; 74(6):1045-50. DOI: 10.1136/annrheumdis-2013-204858. View

18.

Gladman D, Ye J, Chandran V, Lee K, Cook R . Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. J Rheumatol. 2021; 48(12):1824-1829. DOI: 10.3899/jrheum.210434. View

19.

Gratacos J, Casado E, Real J, Torre-Alonso J . Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis. 2006; 66(4):493-7. PMC: 1856049. DOI: 10.1136/ard.2006.060079. View

20.

Pournara E, Kormaksson M, Nash P, Ritchlin C, Kirkham B, Ligozio G . Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open. 2021; 7(3). PMC: 8603280. DOI: 10.1136/rmdopen-2021-001845. View